{
    "ticker": "MRNS",
    "name": "Marinus Pharmaceuticals, Inc.",
    "description": "Marinus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative therapeutics for patients suffering from rare and complex neurological disorders. Founded in 2010 and headquartered in Radnor, Pennsylvania, Marinus is committed to advancing treatments that address unmet medical needs, particularly in the area of epilepsy. The company's lead product candidate, ganaxolone, is a novel, oral neuroactive steroid that has shown promise in clinical trials for various forms of epilepsy, including postpartum depression and other indications. Marinus aims to leverage its expertise in neuroscience and pharmacology to bring new hope to patients with debilitating conditions. The company is dedicated to rigorous research and clinical development, striving to improve the quality of life for patients and their families. Marinus Pharmaceuticals is also focused on establishing collaborations with other biopharmaceutical companies and academic institutions to enhance its research and development efforts. With a strong pipeline and a clear vision, Marinus is poised to make significant contributions to the field of neurology and improve outcomes for patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Radnor, Pennsylvania, USA",
    "founded": "2010",
    "website": "https://www.marinuspharma.com",
    "ceo": "Scott Braunstein",
    "social_media": {
        "twitter": "https://twitter.com/MarinusPharma",
        "linkedin": "https://www.linkedin.com/company/marinus-pharmaceuticals"
    },
    "investor_relations": "https://investors.marinuspharma.com",
    "key_executives": [
        {
            "name": "Scott Braunstein",
            "position": "CEO"
        },
        {
            "name": "Michael E. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Neurology",
            "products": [
                "Ganaxolone"
            ]
        }
    ],
    "seo": {
        "meta_title": "Marinus Pharmaceuticals, Inc. | Innovative Neurology Therapeutics",
        "meta_description": "Explore Marinus Pharmaceuticals, Inc., a leader in developing innovative treatments for neurological disorders. Discover the company's mission, pipeline, and commitment to patient care.",
        "keywords": [
            "Marinus Pharmaceuticals",
            "Ganaxolone",
            "Neurology",
            "Epilepsy",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What does Marinus Pharmaceuticals focus on?",
            "answer": "Marinus Pharmaceuticals focuses on developing innovative therapeutics for rare and complex neurological disorders."
        },
        {
            "question": "Who is the CEO of Marinus Pharmaceuticals?",
            "answer": "Scott Braunstein is the CEO of Marinus Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Marinus Pharmaceuticals headquartered?",
            "answer": "Marinus Pharmaceuticals is headquartered in Radnor, Pennsylvania, USA."
        },
        {
            "question": "What is Marinus's lead product candidate?",
            "answer": "Marinus's lead product candidate is ganaxolone, which is being developed for various forms of epilepsy."
        },
        {
            "question": "When was Marinus Pharmaceuticals founded?",
            "answer": "Marinus Pharmaceuticals was founded in 2010."
        }
    ],
    "competitors": [
        "ZGNX",
        "ICPT",
        "AXSM"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BIIB",
        "VRTX"
    ]
}